Perrigo (PRGO)

Executive Summary

Perrigo Company plc is a global leader in self-care and generic pharmaceuticals, with a strong focus on over-the-counter (OTC) products, store-brand drugs, and infant nutrition. Headquartered in Dublin, Ireland, the company leverages its extensive formulation expertise and robust supply chain to deliver affordable health and wellness solutions. As of mid-2026, Perrigo faces a complex operating environment characterized by generic pricing pressures, raw material inflation, and evolving regulatory landscapes. However, its strategic shift toward higher-margin store-brand OTC offerings and investments in infant nutrition are expected to support margin recovery and top-line growth. The company's pipeline, primarily consisting of completed Phase 1 bioequivalence studies, suggests near-term new product launches are limited, but existing commercial product breadth (36 products) provides steady revenue. Perrigo's valuation, estimated at $1.5 billion with 138 million shares outstanding, reflects market expectations of gradual improvement. Key near-term catalysts include upcoming earnings reports and potential strategic portfolio rationalization, which could enhance shareholder value. Overall, Perrigo remains a resilient player in the generic drug space, though growth is likely to be modest.

Upcoming Catalysts (preview)

• Q3 2026Q3 2026 Earnings Release100% success
• Q4 2026Potential Store-Brand OTC Product Launch50% success
• Q3 2026Strategic Portfolio Restructuring Announcement70% success